Vol. 2 No. 1 (2022): January
Reimbursement Recommendations

Galcanezumab (Emgality)

Published January 10, 2022

Key Messages

  • CADTH recommends that Emgality should be reimbursed by public drug plans for the prevention of migraine if certain conditions are met.
  • Emgality should only be covered to prevent migraine attacks in adult patients who have tried at least 2 other types of oral preventive medications.
  • Emgality should only be reimbursed if the patient is being cared for by a physician who has experience managing migraine headaches. Emgality will only be reimbursed for 6 months at a time. Emgality should not be more than the least costly drug of the same class used to prevent migraine.